Fiche société
RemeGen Co., Ltd.
Traitements, essais et publications liés.
Traitements4programmes
Essais3liés
Publications9liées
SourceDBlocale
Traitements
4| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| RC18 160mgThe purpose of this study is to initially observe the safety and effectivity of RC18 in Participants with systemic myasthenia gravis. | Myasthénie | Phase 2 | À vérifier | China | À vérifier |
| RC18 240 mgThe purpose of this study is to initially observe the safety and effectivity of RC18 in Participants with systemic myasthenia gravis. | Myasthénie | Phase 2 | À vérifier | China | À vérifier |
| standard therapyThis is a multi-center, open-label, phase I study. | Lupus | Phase 1 | À vérifier | China | À vérifier |
| RC18 160mgThe purpose of this study is to initially observe the safety and effectivity of RC18 in Participants with systemic myasthenia gravis. | Myasthénie | Phase 2 | À vérifier | China | À vérifier |
Essais cliniques
3| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Telitacicept | Myasthénie | Phase 3 | NCT07249632 | A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG) | RECRUITING |
| Telitacicept | Lupus | Phase 1 | NCT05247203 | Telitacicept Study in Chinese Subjects With Systemic Lupus Erythematosus | COMPLETED |
| RC18 160mg | Myasthénie | Phase 2 | NCT04302103 | A Study of TACI（Transmembrane Activator and Calcium-modulator and Cyclophilin Ligand (CAML) Interactor）-Antibody Fusion Protein Injection (RC18) in Subjects With Systemic Myasthenia Gravis | COMPLETED |
Publications
9| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| standard therapy | The effects of asymmetrical versus symmetrical high-flow nasal cannula on respiratory muscle activity in acute hypoxaemic respiratory failure and chronic obstructive pulmonary disease: A randomised crossover study. | Pulmonology | ||
| standard therapy | Effect of oral calcium carbonate on uterine contractility: a pilot randomised controlled trial. | Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology | ||
| standard therapy | Achievement of real-world adapted DORIS remission targets among patients with systemic lupus erythematosus initiating belimumab in the USA: A retrospective, observational, cohort study. | Lupus | ||
| standard therapy | Peptide-Based Nanocomplexes Enable Transferrin-Mediated Uptake and p53-Driven Antitumor Activity in 2D and 3D Glioblastoma Models. | International journal of molecular sciences | ||
| standard therapy | Efficacy and Safety of Canakinumab Compared With Standard Therapy for the Treatment of Non-Small Cell Lung Cancer (NSCLC): A Systematic Review. | Cancer reports (Hoboken, N.J.) | ||
| standard therapy | Prior decompensation Identifies Patients at High Mortality Risk Despite Standard Therapy After Variceal Hemorrhage: An IPD Meta-analysis. | Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association | ||
| RC18 240 mg | Telitacicept, a novel humanized, recombinant TACI-Fc fusion protein, for the treatment of systemic lupus erythematosus. | Drugs of today (Barcelona, Spain : 1998) | ||
| standard therapy | Successful Trifarotene Treatment of a Typical Kyrle's Disease With Overview of Topical Therapies. | Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) | ||
| standard therapy | Accelerated recovery and alleviated pain by oral whey protein in herpes zoster patients: a randomized controlled trial. | Nutrition journal |